← back to medicinal chemistry

medicinal chemistry unit 5 study guides

major drug classes in medicinal chemistry

unit 5 review

Medicinal chemistry explores how drugs interact with the body and how the body processes them. This field covers key concepts like pharmacodynamics, pharmacokinetics, and drug-receptor interactions, providing a foundation for understanding how medications work. Major drug classes, including analgesics, antimicrobials, and cardiovascular drugs, are studied in-depth. The course examines their mechanisms of action, structure-activity relationships, and therapeutic applications, as well as the drug design process and safety considerations.

Key Concepts and Terminology

  • Pharmacodynamics studies how drugs interact with target molecules in the body and produce pharmacological effects
  • Pharmacokinetics examines how the body processes drugs through absorption, distribution, metabolism, and excretion (ADME)
  • Bioavailability measures the fraction of an administered drug that reaches systemic circulation unchanged
  • Half-life represents the time required for the concentration of a drug in the body to decrease by half
  • Therapeutic index compares the amount of a drug that causes therapeutic effects to the amount that causes toxicity
    • A higher therapeutic index indicates a safer drug with a larger difference between therapeutic and toxic doses
  • Receptor binding involves the interaction between a drug molecule and its specific target receptor protein
  • Agonists are drugs that bind to receptors and activate them, mimicking the effects of endogenous ligands (acetylcholine)
  • Antagonists bind to receptors but do not activate them, blocking the effects of endogenous ligands or agonists (naloxone)

Major Drug Classes Overview

  • Analgesics relieve pain by acting on the nervous system or peripheral pain mechanisms (opioids, NSAIDs)
  • Antimicrobials treat infections caused by bacteria, viruses, fungi, or parasites (antibiotics, antivirals, antifungals)
    • Antibiotics specifically target bacterial infections and can be broad-spectrum or narrow-spectrum (penicillins, cephalosporins)
  • Cardiovascular drugs manage conditions related to the heart and blood vessels (antihypertensives, anticoagulants)
  • Central nervous system (CNS) drugs act on the brain and spinal cord to treat neurological and psychiatric disorders (antidepressants, antipsychotics)
  • Endocrine system drugs regulate hormonal imbalances or treat hormone-related diseases (insulin, thyroid hormones)
  • Chemotherapeutic agents are used to treat cancer by targeting rapidly dividing cells or specific molecular pathways (cisplatin, targeted therapies)
  • Immunomodulators modify the immune system's response, either suppressing or enhancing its activity (corticosteroids, monoclonal antibodies)

Pharmacological Mechanisms

  • Receptor agonism occurs when a drug binds to and activates a receptor, triggering downstream signaling pathways
  • Receptor antagonism involves a drug binding to a receptor without activating it, preventing the binding of endogenous ligands or agonists
  • Enzyme inhibition reduces the activity of target enzymes, disrupting specific biochemical processes (ACE inhibitors)
    • Competitive inhibitors compete with the substrate for the active site of the enzyme
    • Non-competitive inhibitors bind to allosteric sites, altering the enzyme's conformation and reducing its activity
  • Ion channel modulation alters the function of ion channels, influencing the flow of ions across cell membranes (calcium channel blockers)
  • Transporter inhibition blocks the activity of transporters responsible for the uptake or efflux of specific molecules (serotonin reuptake inhibitors)
  • Receptor desensitization occurs when prolonged exposure to an agonist reduces the receptor's responsiveness over time (beta-2 adrenergic receptor desensitization)
  • Enzyme induction increases the synthesis of target enzymes, leading to enhanced metabolic activity (cytochrome P450 induction)

Structure-Activity Relationships

  • Chemical structure determines a drug's physicochemical properties, target interactions, and pharmacological effects
  • Functional groups are specific arrangements of atoms within a molecule that confer distinct chemical properties and reactivity
    • Substitution of functional groups can alter a drug's potency, selectivity, or pharmacokinetic properties
  • Stereochemistry refers to the three-dimensional arrangement of atoms in a molecule, which can significantly impact drug-target interactions
    • Enantiomers are mirror-image molecules that can exhibit different pharmacological profiles (R-thalidomide, S-thalidomide)
  • Bioisosteres are functional groups or substructures that can be substituted while retaining similar biological activity
  • Quantitative structure-activity relationship (QSAR) models mathematically relate chemical structure to biological activity, guiding drug optimization
  • Pharmacophores are the essential structural features of a drug molecule responsible for its pharmacological activity
  • Homology modeling predicts the three-dimensional structure of a target protein based on its amino acid sequence and known structures of related proteins

Drug Design and Development

  • Target identification involves selecting a specific molecular target (receptor, enzyme) associated with a disease or condition
  • High-throughput screening (HTS) rapidly assesses large compound libraries for activity against a chosen target
  • Lead optimization improves the potency, selectivity, and pharmacokinetic properties of lead compounds through iterative chemical modifications
  • In vitro testing evaluates drug candidates in cell-based or biochemical assays to assess their efficacy and safety
  • In vivo testing assesses drug candidates in animal models to determine their pharmacological effects, toxicity, and pharmacokinetic properties
    • Preclinical studies are conducted in animals to establish safety and efficacy before human trials
  • Clinical trials are conducted in human volunteers to evaluate the safety, efficacy, and optimal dosing of drug candidates
    • Phase 1 trials assess safety and pharmacokinetics in a small group of healthy volunteers
    • Phase 2 trials evaluate efficacy and side effects in a larger group of patients with the target condition
    • Phase 3 trials are large-scale studies that confirm efficacy and safety in a broader patient population
  • Regulatory approval is required before a drug can be marketed, based on the results of preclinical and clinical studies

Therapeutic Applications

  • Hypertension is treated with antihypertensive drugs that lower blood pressure through various mechanisms (ACE inhibitors, beta-blockers)
  • Diabetes mellitus is managed with insulin or oral hypoglycemic agents that regulate blood glucose levels (metformin, sulfonylureas)
  • Depression is treated with antidepressants that modulate neurotransmitter systems in the brain (SSRIs, SNRIs)
    • Selective serotonin reuptake inhibitors (SSRIs) increase serotonin levels by blocking its reuptake (fluoxetine)
    • Serotonin-norepinephrine reuptake inhibitors (SNRIs) block the reuptake of both serotonin and norepinephrine (venlafaxine)
  • Infectious diseases are treated with antimicrobial agents that target specific pathogens (antibiotics for bacterial infections, antivirals for viral infections)
  • Cancer is treated with chemotherapeutic agents that target rapidly dividing cells or specific molecular pathways involved in tumor growth (cisplatin, targeted therapies)
  • Asthma is managed with bronchodilators that relax airway smooth muscle and corticosteroids that reduce inflammation (albuterol, fluticasone)
  • Alzheimer's disease is treated with cholinesterase inhibitors that increase acetylcholine levels in the brain (donepezil)

Side Effects and Safety Considerations

  • Adverse drug reactions (ADRs) are unintended and harmful effects that occur at normal therapeutic doses
    • Type A reactions are dose-dependent and predictable based on the drug's pharmacology (anticholinergic effects of tricyclic antidepressants)
    • Type B reactions are idiosyncratic and not related to the drug's pharmacology (penicillin allergies)
  • Drug-drug interactions occur when one drug alters the pharmacokinetics or pharmacodynamics of another drug (CYP450 inhibition)
  • Contraindications are conditions or factors that preclude the use of a drug due to an unacceptably high risk of adverse effects (pregnancy, certain medical conditions)
  • Therapeutic drug monitoring (TDM) involves measuring drug concentrations in the blood to optimize dosing and minimize toxicity (lithium, vancomycin)
  • Pharmacogenomics studies how genetic variations influence an individual's response to drugs, guiding personalized therapy
  • Teratogenicity refers to a drug's potential to cause birth defects when administered during pregnancy (thalidomide)
  • Black box warnings are the strictest labeling requirements for drugs with serious or life-threatening risks (antidepressants, anticoagulants)
  • Precision medicine aims to tailor drug therapy based on an individual's genetic profile, disease subtype, or other specific factors
  • Targeted drug delivery systems aim to selectively deliver drugs to specific tissues or cells, minimizing off-target effects (antibody-drug conjugates)
  • Nanotechnology involves the use of nanoscale materials and devices for drug delivery, diagnosis, and imaging (liposomes, polymeric nanoparticles)
  • Biologics are drugs derived from living organisms or their products, including proteins, antibodies, and nucleic acids (monoclonal antibodies, gene therapies)
    • Monoclonal antibodies are engineered antibodies that target specific antigens, used for cancer treatment and autoimmune disorders (rituximab, adalimumab)
  • Combination therapies involve the use of multiple drugs with different mechanisms of action to achieve synergistic effects or overcome drug resistance (HIV treatment)
  • Drug repurposing identifies new therapeutic applications for existing drugs, reducing the time and cost of drug development (sildenafil)
  • Artificial intelligence (AI) and machine learning (ML) are being applied to various aspects of drug discovery and development, from target identification to clinical trial design
  • Organ-on-a-chip technologies are microfluidic devices that mimic the structure and function of human organs, providing more predictive models for drug testing